Fig. 2From: Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registryAntithrombotic prescription patterns at baseline in eligible patients from China at Phase III and Phase II.AP, antiplatelet therapy; NOAC, non-VKA oral anticoagulant; VKA, vitamin K antagonist. None indicates no antithrombotic treatmentBack to article page